肝斑（かんぱん）はただのシミじゃない？　日本人の肌に「トランサミン」が効く本当の理由(患者さんむけ)

今回は、多くの女性を悩ませる「肝斑（かんぱん）」について、少しだけ深く、でも分かりやすく解説してみたいと思います。

「肝斑にはトランサミン（トラネキサム酸）が良い」と聞いたことがある方は多いかもしれません。

でも、なぜ効くのか、そもそも肝斑とは何なのか、その本当の理由をご存知でしょうか？

◎アジア人の肌は「炎症の記憶が色として残る」

まず大前提として、同じ肝斑でも、欧米人（白人系）と私たちアジア人とでは、少しタイプが違います。

欧米人の場合、紫外線やホルモンバランスの変化（妊娠やピルなど）が直接的な引き金になることが多いのですが、私たちアジア人の肌は、もともと「メラニン（色素）」を作る工場がとても敏感です。

ちょっとした摩擦、少しの熱、あるいは過去の炎症……そうした「肌へのわずかな刺激の記憶」が、すぐに色（シミ）として残ってしまう体質を持っています。

肝斑の正体は「メラニンの暴走」ではなく「肌の土台のSOS」

これまでの肝斑治療は、「メラニンが暴走しているから、なんとかして消そう！」という考え方が主流でした。

しかし最新の研究では、肝斑の正体は単なる表面のシミではなく、「慢性的な光老化（紫外線ダメージによる老化）」であることが分かってきています。

肝斑ができている肌の奥底（真皮）では、以下のようなことが起きています。

肌の土台（基底膜）がボロボロになっている
肌の奥で、慢性的な「炎症」が起きている
余分な「血管」が増え、赤みが潜んでいる

つまり、肌の奥が火事になっていて、そのSOSサインとして表面の細胞に「もっとメラニンを作って肌を守れ！」という命令が出っ放しになっている状態。

これが肝斑の正体なのです。

◎トランサミンは「漂白剤」ではなく「優秀な消火器」

ここで登場するのがトランサミン（トラネキサム酸）です。

よく誤解されがちなのですが、トランサミンはメラニンを直接白くする「漂白剤」ではありません

では何をしているのかというと、肌の奥で起きている火事を鎮める「消火器」のような役割を果たしています。

1. 命令をストップ：細胞同士の「黒くなれ！」というやり取り（プラスミンなどの刺激信号）をブロックします。
2. 炎症を鎮める：肌の奥のザワザワとした炎症を落ち着かせます。
3. 血管へのアプローチ：肝斑の原因となる余分な血管の働き（赤み）を抑えます。

このように、肝斑の「火種」を根本から静かにしてくれるからこそ、トランサミンは効果を発揮するのです。

◎肝斑治療の鉄則：「攻め」の前に「守り」から

肝斑の下には、ボロボロになった土台と炎症が隠れています。

そのため、いきなり「強いレーザーでシミを削り取る！」といった攻めの治療をすると、かえって火事に油を注ぎ、肝斑が濃くなってしまうことがあります。

アジア人の肝斑治療は、まず「土台を静めること」が最優先です。

徹底した紫外線対策（遮光）
絶対にこすらない（摩擦回避）
トランサミンやビタミンCなどの内服・外用

これらで肌の炎症性のザワつきを鎮め、土台をしっかり整えてから、必要に応じてマイルドな光治療やレーザーを慎重に組み合わせるのが一番の近道です。

◎薬に関する注意点

トランサミンは肝斑にとても有効ですが、美容目的で「とりあえずずっと飲み続ける」ものではありません。

血栓（血の塊）のリスクを上げる可能性があるため、ピルを飲んでいる方、喫煙習慣がある方、その他ご持病がある方は注意が必要です。

「肌の炎症とメラニンのやり取りを、一時的に鎮めてあげるお薬」として、医師と相談しながら正しく使いましょう！

いかがでしたでしょうか？

肝斑は「消して終わり」ではなく、肌の土台からのケアが必要です。

正しい知識を持って、焦らず丁寧に肌と向き合っていきましょう！

Melasma: More Than a Dark Spot

Why Tranexamic Acid May Help, Especially in Asian Skin

Melasma is one of the most common causes of facial pigmentation, particularly among women. While it is often described simply as a type of “hyperpigmentation,” our understanding of melasma has evolved considerably over the past two decades.

Today, researchers recognize that melasma is more than an excess of pigment. It is a complex condition involving interactions among pigment-producing cells, inflammation, blood vessels, hormones, and long-term sun damage.

Understanding these processes can help explain why treatments such as tranexamic acid are often effective.

Why Melasma Appears Different in Asian Skin

Although melasma occurs in all ethnic groups, its clinical behavior may vary among different skin types.

In lighter-skinned populations, melasma is often strongly associated with ultraviolet exposure, pregnancy, oral contraceptive use, and hormonal fluctuations.

In many Asian patients, however, the skin tends to have a heightened pigmentary response to injury or inflammation. Even relatively minor triggers—including friction, heat, irritation, or previous inflammatory events—may result in increased pigmentation.

Dermatologists sometimes refer to this tendency as a greater susceptibility to post-inflammatory hyperpigmentation. In practical terms, it means that the skin may “remember” inflammation through persistent pigment production.

This may help explain why melasma can be particularly persistent in many Asian individuals.

Melasma Is Not Simply a Problem of Excess Pigment

For many years, melasma was viewed primarily as a disorder of overactive melanocytes, the cells responsible for producing melanin.

While melanocytes remain central to the condition, research now suggests that additional factors play important roles.

Studies have identified several changes within melasma-affected skin, including:

Damage to the basement membrane that separates the epidermis from the deeper dermis
Evidence of chronic ultraviolet-induced skin aging
Increased numbers of blood vessels within affected areas
Persistent low-grade inflammation
Increased activity of mast cells and other inflammatory mediators

These findings suggest that melasma should be viewed not simply as a pigment disorder, but as a condition involving the broader skin microenvironment.

In many patients, the visible pigmentation may represent a downstream consequence of ongoing biological signals within the skin.

How Tranexamic Acid Works

One of the most common misconceptions about tranexamic acid is that it directly “bleaches” or removes pigment.

In reality, its mechanism appears to be quite different.

Tranexamic acid is believed to reduce several of the signaling pathways that contribute to melanocyte activation.

Ultraviolet radiation can activate the plasminogen–plasmin system within the skin, leading to the release of inflammatory mediators and biochemical signals that promote pigment production. By inhibiting this pathway, tranexamic acid may reduce the signals that stimulate melanocytes to produce excess melanin.

Emerging research also suggests that tranexamic acid may influence vascular pathways associated with melasma. Because increased vascular activity appears to contribute to disease persistence in some patients, this effect may represent an additional mechanism of benefit.

Rather than directly removing pigment, tranexamic acid appears to reduce some of the underlying biological processes that drive pigmentation.

Why a Gentle Approach Often Works Best

One important lesson from modern melasma research is that more aggressive treatment is not always better.

Because inflammation itself can worsen pigmentation, treatments that excessively irritate the skin may sometimes aggravate melasma rather than improve it.

For this reason, many dermatologists emphasize establishing a healthy skin environment before pursuing more aggressive interventions.

Core treatment strategies often include:

Consistent daily sun protection
Avoidance of unnecessary friction or irritation
Appropriate topical therapies
Oral or topical tranexamic acid when indicated
Antioxidant therapies such as vitamin C
Careful support of the skin barrier

Only after inflammation is adequately controlled should light- or laser-based therapies be considered, and even then, treatment should be individualized.

A Note on Safety

Although tranexamic acid is widely used and generally well tolerated, it is not appropriate for everyone.

Because the medication may increase the risk of blood clots in susceptible individuals, physicians typically review factors such as:

Personal or family history of thromboembolic disease
Oral contraceptive use
Smoking status
Cardiovascular risk factors
Planned surgery or prolonged immobilization

Patients should always discuss potential risks and benefits with their healthcare provider before beginning treatment.

The Bottom Line

Melasma is not simply a cosmetic stain that develops on the surface of the skin.

Current evidence suggests that it reflects a complex interaction among pigmentation, inflammation, vascular activity, and chronic sun-induced skin damage.

This broader understanding helps explain why successful treatment often requires more than simply removing pigment. In many cases, the goal is to calm the underlying biological signals that continue to encourage pigment production.

For that reason, treatments such as tranexamic acid may be effective not because they erase pigment directly, but because they help interrupt the processes that allow melasma to persist.

With patience, consistent sun protection, and an individualized treatment plan, many patients can achieve meaningful and lasting improvement.

肝斑の成因とトランサミン治療について(医療者向け)

ある著名ドクターに細かい質問を受けたので、肝斑について私見をまとめておきたいと思います。

まず、国際学会にでていると、肝斑の定義は国によって少しずれている様に思います。

臨床的に言うと、アジア人の肝斑は「メラニン過剰＋炎症後色素沈着体質＋真皮老化」の比重が強く、欧米、特に白人系の肝斑は「紫外線・ホルモン・光老化・血管反応」が前面に出やすい、という印象です。

ただし、これは人種で完全に二分できるものではなく、Fitzpatrick skin type、日光曝露、妊娠・ホルモン、炎症体質、レーザー歴で大きく変わります。

肝斑の本体は、単なる「メラノサイトが暴走している病気」ではなく、最近はむしろ慢性光老化性の色素・血管・基底膜疾患として見る方がしっくり来ます。

Kangらの韓国人女性56例の病理では、病変部でメラニン量、メラノサイト数、メラノソーム分布、さらにsolar elastosisが増えており、表皮だけでなく真皮の光老化が関与していることが示されています。
British Journal of Dermatology, 2002;146:228–237。

僕の理解では、アジア人の肝斑は、もともとメラノサイトの反応性が高く、わずかな炎症・摩擦・熱・レーザー刺激でも色素に振れやすい。

つまり「炎症の記憶が色として残る皮膚」です。

そこに紫外線、可視光、女性ホルモン、ストレス、皮膚バリア低下が重なり、ケラチノサイト、線維芽細胞、血管内皮、肥満細胞が互いにメラノサイトを刺激する。

一方、欧米白人系では肝斑そのものの頻度は相対的に低く、出る場合は妊娠・経口避妊薬・ホルモン補充・日光曝露との関連が見えやすい印象があります。

世界調査でも紫外線とホルモン因子が肝斑の発症・慢性化に関与することが示されています。
Journal of the European Academy of Dermatology and Venereology, 2009;23:1254–1262

重要なのは、肝斑の下にはしばしば基底膜の破綻、真皮のsolar elastosis、血管新生、肥満細胞増加があることです。

Kwonらの総説は、肝斑を表皮性色素だけでなく、細胞外マトリックス異常、基底膜障害、血管増生、肥満細胞増加を伴う不均一な病態として整理しています。
International Journal of Molecular Sciences, 2016;17:824

ここでトランサミン、つまりトラネキサム酸が効く理由です。

一言で言えば、トランサミンは「メラニンを直接漂白する薬」ではなく、紫外線・炎症・血管反応からメラノサイトへ入る刺激信号を弱める薬と考えるのがよいと思います。

古典的には、紫外線を受けたケラチノサイトではプラスミノーゲン／プラスミン系が活性化します。

するとアラキドン酸、プロスタグランジン、炎症性メディエーターが増え、メラノサイトが刺激される。

トラネキサム酸はこのプラスミン系を抑えることで、ケラチノサイトからメラノサイトへの「黒くなれ」という指令を減らす。

Maeda & Tomitaは、トラネキサム酸がメラノサイト単独ではチロシナーゼ活性を直接下げず、ケラチノサイト培養上清がある条件でメラニン生成を抑えることを示しました。

ここが非常に大事です。
Journal of Health Science, 2007;53:389–396

さらに最近の理解では、トラネキサム酸は血管にも効いている可能性があります。

肝斑では真皮血管やVEGF関連シグナルが関与し、赤み・血管反応がメラノサイト刺激に連動する。

Zhuらは、トラネキサム酸がVEGF受容体を標的にして血管新生とメラニン生成を抑える可能性を示しています。
International Journal of Medical Sciences, 2020;17:903–911

したがって僕の仮説はこうです。

アジア人の肝斑は、メラノサイトの病気というより、「光老化した真皮の上に乗った、過敏なメラニン産生システム」なのだと思います。

基底膜が弱り、真皮に炎症と血管反応があり、肥満細胞が増え、ケラチノサイトが刺激因子を出し続ける。

その結果、表皮のメラノサイトが常に半覚醒状態になる。

そこに紫外線、摩擦、熱、レーザー、ホルモン変動が入ると、一気に色が濃くなる。

トランサミンはその中で、

プラスミン系を抑える
プロスタグランジン系の刺激を下げる
ケラチノサイト・メラノサイト間の信号を弱める
血管新生・VEGF系を抑える可能性がある

という複数の作用で、肝斑の「火種」を静かにしているのだと思います。

だから効き方も、ハイドロキノンのような「色素を削る」感じではなく、新しく濃くなる勢いを止め、肌の炎症性のざわつきを鎮めるような効き方になります。

肝斑が再発しやすいのも、メラニンそのものを消しても、下にある真皮老化・血管・炎症・基底膜破綻が残っていれば、またスイッチが入るからです。

臨床的には、アジア人の肝斑に対しては「攻めるレーザー」よりも、まず遮光、摩擦回避、抗炎症、トランサミン、ビタミンC、外用、低刺激なEBMDで土台を静かにしてから、必要なら慎重に光治療を組み立てる方が理にかなっています。

そうした内服薬やレーザーで綺麗に治った肝斑も観察すると経時的には再生する時には血管周囲から再生してゆくのがよくわかります。

ただし内服トラネキサム酸は、血栓リスク、ピル内服、喫煙、既往歴、周術期などの確認が必要です。

肝斑に効くからといって美容目的で漫然と長期投与する薬ではなく、「血管・炎症・メラニンのクロストークを一時的に鎮める薬」として使うのがよいと思いますね。

On the Pathogenesis of Melasma and the Rationale for Tranexamic Acid Therapy: A Personal Perspective for Clinicians

A well-known colleague recently asked me several detailed questions regarding melasma, which prompted me to organize my current thoughts on the subject.

One observation from attending international meetings is that the clinical concept of melasma appears to vary subtly across regions and ethnic populations.

From a practical clinical standpoint, melasma in Asian patients often seems to represent a combination of excessive melanogenesis, a strong propensity toward post-inflammatory hyperpigmentation, and underlying dermal aging. In contrast, melasma in Western populations—particularly among lighter-skinned Caucasian individuals—appears more strongly associated with ultraviolet exposure, hormonal influences, photoaging, and vascular reactivity.

Naturally, this distinction should not be viewed as a strict racial dichotomy. The phenotype is profoundly influenced by Fitzpatrick skin type, cumulative sun exposure, pregnancy-related and hormonal factors, inflammatory susceptibility, and previous laser or energy-based treatments.

Increasingly, I find it difficult to regard melasma simply as a disorder of hyperactive melanocytes. Rather, contemporary evidence supports viewing it as a chronic photoaging-associated disorder involving pigmentation, vasculature, and basement membrane dysfunction.

In a histopathological study of 56 Korean women with melasma, Kang and colleagues demonstrated not only increased melanin content, melanocyte density, and melanosome distribution within lesional skin, but also significant solar elastosis, suggesting that dermal photoaging contributes substantially to disease pathogenesis rather than being confined to the epidermis alone (British Journal of Dermatology, 2002;146:228–237).

My own interpretation is that many Asian patients possess highly reactive melanocytes that readily respond to minimal inflammatory stimuli, friction, heat exposure, or laser-induced injury. In essence, their skin retains an “inflammatory memory” that manifests clinically as pigmentation.

Upon this background, ultraviolet radiation, visible light, hormonal fluctuations, psychological stress, and impairment of the epidermal barrier create a microenvironment in which keratinocytes, fibroblasts, endothelial cells, and mast cells continuously stimulate melanocyte activity.

By comparison, melasma itself is relatively less common among lighter-skinned Western populations. When it does occur, its association with pregnancy, oral contraceptives, hormone replacement therapy, and cumulative sun exposure is often more readily apparent. A large international survey similarly identified ultraviolet radiation and hormonal influences as major contributors to both the onset and chronicity of melasma (Journal of the European Academy of Dermatology and Venereology, 2009;23:1254–1262).

An important concept is that melasma frequently exists upon a background of basement membrane disruption, solar elastosis, neovascularization, and increased mast-cell infiltration.

The comprehensive review by Kwon and colleagues elegantly reframed melasma as a heterogeneous disorder involving not only epidermal pigmentation but also extracellular matrix abnormalities, basement membrane damage, vascular proliferation, and mast-cell activation (International Journal of Molecular Sciences, 2016;17:824).

This broader perspective helps explain the clinical efficacy of tranexamic acid.

Tranexamic acid should not be considered a direct depigmenting or “bleaching” agent. Rather, it appears to attenuate the upstream signaling pathways through which ultraviolet radiation, inflammation, and vascular activation communicate with melanocytes.

Classically, ultraviolet exposure activates the plasminogen–plasmin system within keratinocytes. This leads to increased production of arachidonic acid metabolites, prostaglandins, and other inflammatory mediators that subsequently stimulate melanogenesis.

By inhibiting plasmin activity, tranexamic acid reduces the transmission of these pro-pigmentary signals from keratinocytes to melanocytes.

A seminal study by Maeda and Tomita demonstrated that tranexamic acid does not directly suppress tyrosinase activity in isolated melanocytes. Instead, its inhibitory effect on melanogenesis becomes evident in the presence of keratinocyte-conditioned media, indicating that the drug primarily modulates intercellular signaling rather than melanocyte enzymatic activity itself (Journal of Health Science, 2007;53:389–396).

This distinction is fundamentally important.

More recent evidence suggests that tranexamic acid may also exert vascular effects. Vascular proliferation and VEGF-related signaling pathways are increasingly recognized as contributors to melasma, linking erythema and vascular reactivity to melanocyte stimulation.

Zhu and colleagues reported that tranexamic acid may suppress both angiogenesis and melanogenesis through modulation of VEGF receptor signaling pathways (International Journal of Medical Sciences, 2020;17:903–911).

Based on these observations, my working hypothesis is as follows:

Melasma in Asian skin may be less a primary melanocyte disorder than a hyperresponsive melanogenic system operating upon a chronically photoaged dermal environment.

The basement membrane becomes compromised. Dermal inflammation and vascular reactivity persist. Mast cells accumulate. Keratinocytes continuously release stimulatory mediators.

As a result, epidermal melanocytes remain in a state of chronic partial activation.

When ultraviolet exposure, friction, heat, laser injury, or hormonal fluctuations are superimposed upon this background, pigmentation rapidly intensifies.

Within this framework, tranexamic acid may exert therapeutic benefit through multiple complementary mechanisms:

Inhibition of the plasminogen–plasmin pathway
Reduction of prostaglandin-mediated inflammatory signaling
Attenuation of keratinocyte–melanocyte communication
Potential suppression of angiogenesis and VEGF-related pathways

In other words, tranexamic acid appears to suppress the underlying “ignition sources” of melasma rather than directly removing pigment.

This may explain why its clinical effects differ from those of hydroquinone. Whereas hydroquinone primarily reduces existing pigment, tranexamic acid often appears to slow the development of new pigmentation and dampen the chronic inflammatory activity of the skin.

The well-known tendency of melasma to recur may reflect the fact that eliminating melanin alone does not correct the underlying dermal photoaging, vascular abnormalities, inflammatory signaling, or basement membrane damage. As long as these pathological substrates persist, the disease can be reactivated.

From a practical clinical perspective, treatment of melasma in Asian patients may therefore be most rational when focused initially on photoprotection, avoidance of frictional injury, anti-inflammatory strategies, tranexamic acid, vitamin C-based therapies, topical treatments, and low-inflammatory energy-based modalities. More aggressive laser interventions can then be considered cautiously once the cutaneous environment has been stabilized.

Interestingly, even in cases that achieve excellent clearance following oral therapy or laser treatment, longitudinal observation often reveals recurrence beginning around the perivascular regions, further suggesting an important vascular component in disease reactivation.

Finally, oral tranexamic acid is not a benign cosmetic supplement. Careful assessment of thromboembolic risk, smoking status, oral contraceptive use, past medical history, and perioperative considerations remains essential.

Rather than viewing tranexamic acid as a medication for indefinite cosmetic use, I believe it is best understood as a therapeutic agent that temporarily suppresses the pathological crosstalk among vascular, inflammatory, and melanogenic pathways that sustain melasma.